Serum lactate dehydrogenase is associated with impaired lung function: NHANES 2011–2012

Sheng Hu; Jiayue Ye; Qiang Guo; Sheng Zou; Wenxiong Zhang; Deyuan Zhang; Yang Zhang; Silin Wang; Lang Su; Yiping Wei

doi:10.1371/journal.pone.0281203

Peer Review History

Original SubmissionOctober 26, 2022
6 Dec 2022 Decision Letter - Gulali Aktas, Editor PONE-D-22-29185Serum lactate dehydrogenase is associated with impaired lung function: NHANES 2011-2012PLOS ONE Dear Dr. Wei, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ACADEMIC EDITOR: Authors should revise their manuscript according to the suggestions of the reviewers. There is some novelty but the paper must be improved, accordingly. Please submit your revised manuscript by Jan 15 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Gulali Aktas Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following financial disclosure: "This study was supported by grants from the National Natural Science Foundation of China [grant numbers 81860379, 82160410] and the Science and Technology Planning Project at the Department of Science and Technology of Jiangxi Province, China [grant number 20171BAB 205075]." Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. Thank you for stating the following in the Funding Section of your manuscript: "This study was supported by grants from the National Natural Science Foundation of China [grant numbers 81860379, 82160410] and the Science and Technology Planning Project at the Department of Science and Technology of Jiangxi Province, China [grant number 20171BAB 205075]." We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "This study was supported by grants from the National Natural Science Foundation of China [grant numbers 81860379, 82160410] and the Science and Technology Planning Project at the Department of Science and Technology of Jiangxi Province, China [grant number 20171BAB 205075]." Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: Authors should revise their manuscript according to the suggestions of the reviewers. There is some novelty but the paper must be improved, accordingly. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ******** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ****** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ****** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ****** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Increased muscle LDH activity has been found in elderly male patients with chronic obstructive pulmonary disease (COPD) who are susceptible to contractile fatigue of the quadriceps femoris muscle following exercise. (Spruit, M. A., Pennings, H. J., Möller, G. M., Janssen, P. P., & Wouters, E. F. M. (2008). Serum LDH and exercise capacity in COPD. Thorax, 63(5), 472-472 ) Plasma lactate dehydrogenase (LDH) can be induced by hypoxia and is found to be increased in multiple patients diagnosed with IPF, but its relation to IPF severity is less known.( Åttingsberg, E., Hoyer, N., Wilcke, T., Prior, T. S., Bendstrup, E., & Shaker, S. (2019). Lactate dehydrogenase as a biomarker of advanced disease in idiopathic pulmonary fibrosis)….. Since the correlation between LDH level and PFT is examined, LDH studies in lung diseases should be given more attention.The role of LDH level in disease activity and response to treatment in lung diseases can also be mentioned. Studies can also be mentioned about the increase in LDH level with smoking. Reviewer #2: The authors suggest the lactate dehydrogenase as a new serological monitoring indicator for patients suffering from respiratory diseases and has implications for patients with possible clinical impairment of pulmonary function. The manuscript Eur Respir J . 1996 Aug;9(8):1736-42. doi: 10.1183/09031936.96.09081736 evidences the LDH involvement with lung diseases. However, the present study addressed the LDH role on worse of pulmonary ventilation in lung diseases. It is a new information. ****** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ******** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. https://doi.org/10.1371/journal.pone.0281203.r001
Revision 1
7 Dec 2022 Author Response Dear Gulali Aktas and Reviewers: Thank you for your letter and for the comments concerning our manuscript entitled “Serum lactate dehydrogenase is associated with impaired lung function: NHANES 2011-2012”. We are very sorry for submitting the revised manuscript so late. The reviewers’ comments are all valuable and helpful for revising and improving our paper, as well providing important guiding significance to our research. We have studied the comments carefully and have made corrections that we hope will meet with approval. The main corrections of this article and the point-by-point responses to the editor and reviewers’ comments are detailed below. Editor: 1.- Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. Response: Thank you for your professional advice. We have revised the manuscript according to PLOS ONE style requirements, including the requirements for file naming. See the revised manuscript for details. 2.- Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter. Response: Thank you for your careful reading of our manuscript. We have clarified in our newly uploaded cover letter that funders have no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 3.- Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Please include your amended statements within your cover letter. Response: Thank you for your professional comments concerning our manuscript. We have removed any grant-related text from the manuscript and have included a corrected grant statement in the cover letter. 4.- Please review your reference list to ensure that it is complete and correct. Response: Thank you for carefully reading our manuscript. Based on your comments, we have corrected the cited sources in reference 6. Based on your professional opinion, we found that some of the withdrawn low-quality literature was incorrectly cited. Therefore, we have removed the original references 29, 30 and 45 from the manuscript. Based on your and the reviewers' valuable comments, we have added citations 16, 17, 45, 49 and 50. See the reference section of the manuscript for details. Reviewer #1: Increased muscle LDH activity has been found in elderly male patients with chronic obstructive pulmonary disease (COPD) who are susceptible to contractile fatigue of the quadriceps femoris muscle following exercise. (Spruit, M. A., Pennings, H. J., Möller, G. M., Janssen, P. P., & Wouters, E. F. M. (2008). Serum LDH and exercise capacity in COPD. Thorax, 63(5), 472-472 ) Plasma lactate dehydrogenase (LDH) can be induced by hypoxia and is found to be increased in multiple patients diagnosed with IPF, but its relation to IPF severity is less known.( Åttingsberg, E., Hoyer, N., Wilcke, T., Prior, T. S., Bendstrup, E., & Shaker, S. (2019). Lactate dehydrogenase as a biomarker of advanced disease in idiopathic pulmonary fibrosis) Since the correlation between LDH level and PFT is examined, LDH studies in lung diseases should be given more attention.The role of LDH level in disease activity and response to treatment in lung diseases can also be mentioned. Studies can also be mentioned about the increase in LDH level with smoking. Response: Thank you for your professional comments. All these references are very valuable to our article. We have modified the article as follows based on your valuable comments. 1) Added lines 319-320 “Previous studies have suggested that LDH levels are associated with lung disease. In recent years,” 2) Added lines 323-329 “In fact, LDH levels have important implications in pulmonary disease activity and response to therapy……Spruit et al. showed that increased muscle LDH activity was found in older men with COPD and that resting serum LDH activity was increased in COPD patients compared to healthy smoking and non-smoking peers”. 3) Added lines 75-78 “The relationship between……in the serum of COPD patients and smoking patients”. 4) Added citations for references 16, 17, 49, 50. Thank you for considering our manuscript and putting forward such professional and constructive opinions to help us improve the quality of the manuscript. Reviewer #2: The authors suggest the lactate dehydrogenase as a new serological monitoring indicator for patients suffering from respiratory diseases and has implications for patients with possible clinical impairment of pulmonary function. The manuscript Eur Respir J. 1996 Aug;9(8):1736-42. doi: 10.1183/09031936.96.09081736 evidences the LDH involvement with lung diseases. However, the present study addressed the LDH role on worse of pulmonary ventilation in lung diseases. It is a new information. Response: Thank you very much for your professional opinion and for the superb summary of the main elements of our study. Based on your valuable comments, we have cited reference 45 and the added lines 319-320 “Previous studies have suggested that LDH levels are associated with lung disease. In recent years”. Thank you for considering our study to be somewhat new and for providing such a valuable reference. Thank you again for considering our manuscript and putting forward such professional and constructive opinions to help us improve the quality of the manuscript. Thank you again for your careful reading of our manuscript and professional comments. We tried our best to improve the manuscript and have made some important changes to the manuscript. However, the changes have not influenced the overall framework of the paper. We appreciate the efforts made by the Editors and Reviewers, and hope that the corrections will meet with their approval. We hope to receive a decision soon. Thank you and best wishes Yours sincerely Corresponding author: Name: Yiping Wei E-mail: ndefy08025@ncu.edu.cn Attachments Attachment Submitted filename: Response to Reviewers.docx https://doi.org/10.1371/journal.pone.0281203.r002
18 Jan 2023 Decision Letter - Gulali Aktas, Editor Serum lactate dehydrogenase is associated with impaired lung function: NHANES 2011-2012 PONE-D-22-29185R1 Dear Dr. Wei, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Gulali Aktas Academic Editor PLOS ONE Additional Editor Comments (optional): The paper is revised in accordance with the suggestions of the reviewers. It is acceptable for publication in its current form. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) ******** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: (No Response) ****** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: (No Response) ****** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) ****** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: (No Response) ****** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) ****** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No ******** https://doi.org/10.1371/journal.pone.0281203.r003
Formally Accepted
23 Jan 2023 Acceptance Letter - Gulali Aktas, Editor PONE-D-22-29185R1 Serum lactate dehydrogenase is associated with impaired lung function: NHANES 2011-2012 Dear Dr. Wei: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Professor Gulali Aktas Academic Editor PLOS ONE https://doi.org/10.1371/journal.pone.0281203.r004

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .